Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5526_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Foreword
- •Contents
- •1.1 Introduction
- •1.2 Pathophysiology
- •1.3 Case Presentation
- •1.4 Case Discussion
- •1.5 Clinical Characteristics
- •1.6 Diagnostic Algorithm
- •1.8 Management
- •1.9 Conclusion
- •References
- •2.1 Introduction
- •2.2 Pathophysiology
- •2.3 Case Presentation
- •2.4 Case Discussion
- •2.5 Clinical Characteristics
- •1.7 Differential Diagnosis
- •2.6 Diagnostic Algorithm
- •2.7 Management
- •2.8 Conclusion
- •References
- •3.1 Introduction
- •3.2 Pathophysiology
- •3.3 Case Presentation
- •3.4 Case Discussion
- •3.5 Clinical Characteristics
- •3.6 Diagnostic Algorithm
- •3.7 Management
- •3.8 Conclusion
- •References
- •4.1 Introduction
- •4.2 Pathophysiology
- •4.3 Case Presentation
- •4.4 Case Discussion
- •4.6 Diagnostic Algorithm
- •4.7 Management
- •4.8 Conclusion
- •References
- •5.1 Introduction
- •5.2 Pathophysiology
- •5.3 Case Presentation
- •5.4 Case Discussion
- •5.5 Diagnostic Algorithm
- •5.6 Management
- •5.7 Conclusion
- •References
- •6.1 Introduction
- •6.2 Pathogenesis
- •6.3 Case Presentation
- •6.4 Case Discussion
- •6.5 Diagnostic Algorithm
- •6.6 Management
- •6.7 Conclusion
- •References
- •7.1 Introduction
- •7.2 Pathophysiology
- •7.3 Case Presentation
- •7.5 Differential Diagnosis
- •7.7 The Following Strategies Are Essential
- •7.7.1 Acute Symptom Relief
- •7.7.1.1 Pharmacological Treatment
- •7.7.2.1 Pharmacologic Prophylaxis
- •7.8 Conclusion
- •References
- •8.1 Introduction
- •8.3 Case Study
- •8.4 Case Discussion
- •8.5 Clinical Management
- •8.7 Diagnosis
- •8.8 Treatment
- •8.9 Conclusion
- •References
- •9.1 Introduction
- •9.2 Case Presentation
- •9.4 Diagnosis Algorithm
- •9.5 Secondary SUNCT
- •9.6 Management
- •9.8 Conclusion
- •References
- •10.1 Introduction
- •10.2 Pathophysiology
- •10.3 Case Presentation
- •10.4 Case Discussion
- •10.5 Clinical Characteristics
- •10.6 Diagnostic Algorithm
- •10.7 Management
- •10.8 Conclusion
- •References
- •11.1 Introduction
- •11.2 Pathophysiology
- •11.3 Case Presentation
- •11.4 Case Discussion
- •11.5 Clinical Characteristics
- •11.6 Diagnostic Algorithm
- •11.6.1 Step 1: Detailed Patient History
- •11.8 Management
- •11.9 Conclusions
- •12.2 Pathophysiology
- •12.3 Case Presentation
- •12.4 Case Discussion
- •12.6 Treatment
- •12.7 Conclusion
- •References
- •References
- •12.1 Introduction
- •13.1 Introduction
- •13.2 Pathophysiology
- •13.3 Case Presentation
- •13.4 Case Discussion
- •13.5 Clinical Characteristics
- •13.6 Diagnostic Algorithm
- •13.7 Management
- •13.8 Conclusion
- •References
- •14.1 Introduction
- •14.2 Pathophysiology
- •14.3 Case Presentation
- •14.3.1 Clinical Case 1
- •14.3.2 Clinical Case 2
- •14.4 Case Discussion
- •14.5 Clinical Characteristics
- •14.7 Treatment/Management
- •14.8 Conclusion
- •References
- •15.1 Introduction
- •15.2 Case Presentation
- •15.3 Case Discussion
- •15.4 Diagnostic Algorithm
- •15.5 Pathophysiology
- •15.6 Clinical Presentation
- •15.6.1 External-Compression Headache (ECH)
- •15.6.2 External-Traction Headache (ETH)
- •15.7 Management
- •15.7.1 Nonpharmacological Strategies
- •15.7.2 Pharmacological Strategies
- •15.7.3 Patient Education and Awareness
- •15.8 Conclusion
- •References
- •16.1 Introduction
- •16.2 Pathophysiology
- •16.3 Case Presentation
- •16.4 Case Discussion
- •16.6 Diagnostic Algorithm
- •16.7 Management
- •16.8 Conclusion
- •References
- •17.1 Introduction
- •17.2 Pathophysiology
- •17.3 Case Presentation
- •17.4 Case Discussion
- •17.5 Clinical Characteristics
- •17.6 Diagnosis
- •17.7 Differential Diagnosis
- •17.8 Treatment
- •17.9 Conclusion
- •References
- •18.1 Introduction
- •18.2 Pathophysiology
- •18.3 Case Presentation
- •18.4 Case Discussion
- •18.5 Clinical Presentation
- •18.6 Diagnosis
- •18.7 Differential Diagnosis
- •18.8 Treatment
- •18.9 Conclusion
- •References
- •19.1 Introduction
- •19.2 Pathophysiology
- •19.3 Case Presentation
- •19.4 Case Discussion
- •19.5 Diagnostic Approach
- •19.6 Management
- •19.7 Conclusion
- •References
- •20.1 Introduction
- •20.3 Case Report
- •20.4 Case Discussion
- •20.6 Clinical Presentation
- •20.7 Diagnostic Algorithm
- •20.8 Conclusion
- •References
- •21.1 Introduction
- •21.2 Case Presentation
- •21.3 Clinical Characteristics
- •21.4 Diagnosis
- •21.5 Treatment
- •References
- •22.1 Introduction
- •22.3 Case Presentation 1
- •22.4 Case Discussion
- •22.5 Case Presentation 2
- •22.6 Case Discussion 2
- •22.7 Clinical Characteristics
- •22.8 Diagnostic Workup
- •22.9 Treatment
- •22.10 Prognosis
- •References
- •23.1 Introduction
- •23.2 Pathophysiology
- •23.3 Case Presentation
- •23.4 Case Discussion
- •23.6 Diagnostic Algorithm
- •23.7 Management
- •23.8 Conclusion
- •References
- •24.1 Introduction
- •24.2 Case Presentation
- •24.3 Case Discussion
- •24.4 Pathophysiology
- •24.6 Clinical Characteristics
- •24.8 Treatment Approaches
- •24.10 Conclusion
- •References
- •25.1 Introduction
- •25.2 Case Presentation
- •25.3 Case Discussion
- •25.4 Conclusion
- •References
- •26.1 Introduction
- •26.2 Pathophysiology
- •26.3 Case Presentation
- •26.4 Case Discussion
- •26.5 Clinical Characteristics
- •26.6 Diagnostic Algorithm
- •26.7 Management
- •26.8 Conclusion
- •References
- •27.1 Introduction
- •27.2 Case Presentations
- •27.3 Clinical Characteristics
- •27.4 Discussion
- •27.5 Conclusion
- •References
- •28.1 Introduction
- •28.2 Case Presentation
- •28.3 Case Discussion
- •28.4 Clinical Characteristics
- •28.5 Diagnosis
- •28.6 Conclusion
- •28.7 Key Messages
- •References
- •29.1 Introduction
- •29.2 Pathophysiology
- •29.3 Case Presentation
- •29.4 Clinical Presentation
- •29.5 Diagnosis
- •29.6 Treatment
- •29.7 Conclusion
- •References
- •30.1 Introduction
- •30.2 Clinical Case
- •30.3 Clinical Presentation
- •30.4 Differential Diagnosis
- •30.5 Diagnosis
- •30.6 Treatment
- •30.7 Conclusion
- •References
- •31.1 Introduction
- •31.2 Pathophysiology
- •31.3 Case Presentation
- •31.4 Case Discussion
- •31.5 Clinical Presentation
- •31.7 Conclusion
- •References
- •32.1 Introduction
- •32.2 Pathophysiology
- •32.3 Case Presentation
- •32.4 Case Discussion
- •32.6 Diagnosis
- •32.7 Additional Diagnostic Evaluations
- •32.8 Apply ICHD-3 Diagnostic Criteria [9]
- •32.10 Management
- •32.11 Conclusion
- •References
- •33.1 Introduction
- •33.2 Pathophysiology
- •33.3 Case Presentation
- •33.4 Clinical Characteristics
- •33.5 Diagnostic Algorithm
- •33.6 Treatment
- •33.7 Conclusion
- •References
- •34.1 Introduction
- •34.2 Pathophysiology
- •34.3 Case Presentation
- •34.4 Case Discussion
- •34.6 Diagnostic Algorithm
- •34.7 Treatment
- •34.8 Conclusion
- •References
- •35.1 Introduction
- •35.3 Case Presentation
- •35.4 Case Discussion
- •35.7 Treatment
- •35.7.1 Oxygen Therapy (100% Oxygen)
- •35.8 Conclusion
- •References
- •36.1 Introduction
- •36.2 Pathophysiology
- •36.3 Case Presentation
- •36.5 Diagnostic Algorithm
- •36.6 Treatment
- •36.7 Conclusion
- •References
- •37.1 Introduction
- •37.2 Pathophysiology
- •37.3 Case Presentation
- •37.4 Headache Characteristics
- •37.5 Case Discussion
- •37.6 Treatment
- •37.7 Conclusion
- •References
- •38.1 Introduction
- •38.2 Pathophysiology
- •38.3 Case Presentation
- •38.4 Clinical Presentation
- •38.5 Diagnostic Algorithm
- •38.6 Treatment
- •38.7 Conclusion
- •References
- •39.1 Introduction
- •39.3 Case Presentation
- •39.4 Case Discussion
- •39.6 ICHD-3 Diagnostic Criteria [28]
- •39.6.1 Diagnostic Criteria
- •39.7 Diagnostic Algorithm
- •39.9 Conclusion
- •References
- •40.1 Introduction
- •40.3 Case Presentation
- •40.4 Case Discussion
- •40.5.1 Diagnostic Algorithm
- •40.6 Treatment
- •40.7 Conclusion
- •References
- •41.1 Introduction
- •41.3 Case Presentation
- •41.4 Clinical Presentation
- •41.5 Differential Diagnosis
- •41.6 Conclusion
- •41.7 Key Messages
- •References
- •42.1 Introduction
- •42.2 Pathophysiology
- •42.3 Case Presentation
- •42.5 Case Discussion
- •42.6 Clinical Presentation
- •42.7 Diagnostic Algorithm [9]
- •42.8 Preeclampsia
- •42.9 Eclampsia
- •42.10 Fetal Assessment
- •42.11 Treatment
- •42.12 Antihypertensive Management [8]
- •42.14 Conclusion
- •References
- •43.1 Introduction
- •43.2 Pathophysiology
- •43.3 Case Presentation
- •43.4 Case Discussion
- •43.5 Clinical Manifestations
- •43.6 Diagnosis
- •43.7 Treatment
- •43.8 Conclusion
- •References
- •44.1 Introduction
- •44.2 Pathophysiology
- •44.3 Case Presentation
- •44.4 Case Discussion
- •44.6 Diagnostic Approach
- •44.7 Management
- •44.8 Conclusion
- •References
- •45.1 Introduction
- •45.2 Pathophysiology
- •45.3 Case Presentation
- •45.6 Treatment
- •45.7 Conclusion
- •References
- •46.1 Introduction
- •46.2 Pathophysiology
- •46.3 Case Presentation
- •46.4 Clinical Characteristics
- •46.5 Differential Diagnosis
- •46.6 Treatment
- •46.7 Conclusion
- •References
- •47.1 Introduction
- •47.2 Pathophysiology
- •47.3 Case Presentation
- •47.4 Case Discussion
- •47.5 Clinical Presentations
- •47.6 Diagnostic Algorithm
- •47.7 Differential Diagnosis
- •47.8 Treatment
- •47.9 Conclusion
- •References
- •48.1 Introduction
- •48.2 Pathophysiology
- •48.3 Case Presentation
- •48.4 Case Discussion
- •48.5 Clinical Characteristics
- •48.7 Treatment
- •48.8 Conclusion
- •References
- •49.1 Introduction
- •49.2 Pathophysiology
- •49.3 Case Presentation
- •49.4 Clinical Presentation
- •49.5 Diagnosis
- •49.6 Treatment
- •49.7 Conclusion
- •References
- •50.1 Introduction
- •50.2 Pathophysiology
- •50.3 Case Presentation
- •50.4 Case Discussion
- •50.5 Clinical Characteristics
- •50.6 Diagnosis
- •50.7 Treatment
- •50.8 Conclusion
- •References
- •51.1 Introduction
- •51.2 Case Presentation
- •51.3 Clinical Characteristics
- •51.4 Diagnosis
- •51.5 Treatment
- •51.6 Conclusion
- •References
- •52.1 Introduction
- •52.2 Pathophysiology
- •52.3 Case Presentation
- •52.4 Case Discussion
- •52.5 Clinical Characteristics
- •52.6 Diagnosis
- •52.6.1 Cervicogenic Headache
- •52.6.2 Migraine
- •52.6.3 Neck Pain
- •52.6.4 Demyelinating Lesions
- •52.6.5 Cervical Myelitis
- •52.6.6 Occipital Allodynia
- •52.6.7 Cervical Muscle Spasms
- •52.7 Treatment
- •52.7.2 Acupuncture
- •52.7.3 Transcutaneous Electrical Nerve Stimulations (TENS)
- •52.8 Minimally Invasive Treatment
- •52.8.1 Nerve Blocks
- •52.8.2 Botulinum Toxin A
- •52.8.3 Radio Frequency
- •52.8.4 Occipital Nerve Stimulation
- •52.9 Surgical Treatments
- •52.10 Conclusions
- •References
- •53.1 Introduction
- •53.2 Pathophysiology
- •53.3 Characteristics of Pain
- •53.4 Case Presentation
- •53.5 Case Discussion
- •53.6 Clinical Characteristics
- •53.8 Treatment
- •53.9 Conclusion
- •References
- •54.1 Introduction
- •54.2 Pathophysiology
- •54.3 Case Presentation
- •54.4 Case Discussion
- •54.5 Clinical Characteristics
- •54.6 Diagnostic Algorithm
- •54.7 Management
- •54.8 Conclusion
- •References
- •55.1 Introduction
- •55.2 Pathophysiology
- •55.3 Case Presentation

43 Headache Attributed toHypothyroidism
16. Vincent MB.Fisiopatologia da enxaqueca. Arq Neuropsiquiatr. 1998;56:841–51.
17. Aloisi AM, Vodo S, Buonocore M.Pain and thyroid hormones. Neurol Sci. 2013;34:1501–8.
18. Bauer M, Whybrow PC.Thyroid hormone, neural tissue and mood modulation. World J Biol
Psychiatry. 2001;2:59–69.
19. Hassan WA, Aly MS, Rahman TA, Shahat AS.Impact of experimental hypothyroidism on
monoamines level in discrete brain regions and other peripheral tissues of young and adult male
rats. Int J Dev Neurosci. 2013;31(4):225–33. https://doi.org/10.1016/j.ijdevneu.2013.02.001.
20. Stipcevic T, Kusacic-Kuna S, Dezeljin M, Dodig D, Korsic M, Pivac N, Muck-Seler D.Platelet
serotonin concentration and monoamine oxidase activity in hypothyroid patients. Horm Res.
2009;71(4):207–12. https://doi.org/10.1159/000201109. Epub 2009 Mar 4.
21. Bortolotto VC, Pinheiro FC, Araujo SM, Poetini MR, Bertolazi BS, de Paula MT, Meichtry
LB, de Almeida FP, de Freitas CS, Jesse CR, Prigol M.Chrysin reverses the depressive-like
behavior induced by hypothyroidism in female mice by regulating hippocampal serotonin and
dopamine. Eur J Pharmacol. 2018;822:78–84. https://doi.org/10.1016/j.ejphar.2018.01.017.
22. Ito JM, Valcana T, Timiras PS. Effect of hypo- and hyperthyroidism on regional monoamine metabolism in the adult rat brain. Neuroendocrinology. 1977;24(1):55–64. https://doi.
org/10.1159/000122696.
23. Tousson E, Ibrahim W, Arafa N, Akela M. Monoamine concentrations changes in the PTUinduced hypothyroid rat brain and the ameliorating role of folic acid. Hum Exp Toxicol.
2011;31(3):282–9. https://doi.org/10.1177/0960327111405863.
24. Zhang Q, Feng JJ, Yang S, Liu XF, Li JC, Zhao H.Lateral habenula as a link between thyroid
and serotoninergic system modiates depressive symptoms in hypothyroidism rats. Brain Res
Bull. 2016;124:198–205.
25. Sandrini M, Vitale G, Vergoni AV, Ottani A, Bertolini A.Effect of acute and chronic treatment
with triiodothyronine on serotonin levels and serotonergic receptor subtypes in the rat brain.
Life Sci. 1996;58(18):1551–9.
26. Hela D, Smith S.The effects of acute and repeated administration of T3 to mice on 5-HT1 and
5-HT2 function in the brain and its inuence on the actions of repeated electroconvulsive shock.
Neuropharmacology. 1988;27(12):1239–48.
27. Yu D, Zhou H, Yang Y, Jiang Y, Wang T, Lv L, Zhou Q, Yang Y, Dong X, He J, Huang X, Chen
J, Wu K, Xu L, Mao R. The bidirectional effects of hypothyroidism and hyperthyroidism
on anxiety- and depression-like behaviors in rats. Horm Behav. 2015;69:106–15. https://doi.
org/10.1016/j.yhbeh.2015.01.003.
28. Cleare AJ, McGregor A, Chambers SM, Dawling S, O’Keane V. Thyroxine replacement
increases central 5-hydroxytryptamine activity and reduces depressive symptoms in hypothyroidism. Neuroendocrinology. 1996;64(1):65–9. https://doi.org/10.1159/000127099.
29. Kulikov A, Moreau X, Jeanningros R.Effects of experimental hypothyroidism on 5-HT1A,
5-HT2A receptors, 5-HT uptake sites and tryptophan hydroxylase activity in mature rat brain1.
Neuroendocrinology. 1999;69(6):453–9. https://doi.org/10.1159/000054449.
30. Jin Z, Ling J, Yu J, He M, Ni P, Zhang F, Wang Y.Serotonin 2A receptor function and depressionlike behavior in rats model of hypothyroidism. Exp Brain Res. 2021;239(8):2435–44. https://
doi.org/10.1007/s00221- 021- 06129- 1.
31. Kulikov AV, Jeanningro R. Vliianie gipertireoidizma na 5-HT1A-, 5-HT2A-retseptory i
belok-transporter serotonina v golovnom mozgu krys [Effect of hypothyroidism on 5-HT1A-,
5-HT2A-receptors and serotonin transporter in the rat brain]. Rossiiskii ziologicheskii zhurnal imeni IM Sechenova. 2000;86(3):312–9.
32. Huang J, Fan Y, Jia Y, Hong Y. Antagonism of 5-HT(2A) receptors inhibits the expression
of pronociceptive mediator and enhances endogenous opioid mechanism in carrageenaninduced inammation in rats. Eur J Pharmacol. 2011;654(1):33–41. https://doi.org/10.1016/j.
ejphar.2010.12.007.
33. Wang D, Gao Y, Ji H, Hong Y.Topical and systemic administrations of ketanserin attenuate
hypersensitivity and expression of CGRP in rats with spinal nerve ligation. Eur J Pharmacol.
2010;627(1–3):124–30. https://doi.org/10.1016/j.ejphar.2009.11.011.
https://doi.org/10.1016/0024- 3205(96)00129- 4.
https://doi.org/10.1016/0028- 3908(88)90026- 3.
415

416
34. Okamoto K, Imbe H, Morikawa Y, Itoh M, Sekimoto M, Nemoto K, Senba E. 5-HT2A receptor
subtype in the peripheral branch of sensory bers is involved in the potentiation of inammatory pain in rats. Pain. 2002;99(1–2):133–43.
35. Wang D, Chen T, Gao Y, Quirion R, Hong Y.Inhibition of SNL-induced upregulation of CGRP
and NPY in the spinal cord and dorsal root ganglia by the 5-HT(2A) receptor antagonist ketanserin in rats. Pharmacol Biochem Behav. 2012;101(3):379–86. https://doi.org/10.1016/j.
pbb.2012.02.004.
36. van Hoogstraten WS, MaassenVanDenBrink A.The need for new acutely acting antimigraine
drugs: moving safely outside acute medication overuse. J Headache Pain. 2019;20(1):54.
https://doi.org/10.1186/s10194- 019- 1007- y.
37. Bruno AN, Pochmann D, Ricachenevsky FK, Fontella FU, Bonan CD, Dalmaz C, BarretoChaves ML, Sarkis JJ.Nociceptive response and adenine nucleotide hydrolysis in synaptosomes isolated from spinal cord of hypothyroid rats. Neurochem Res. 2005;30(9):1155–61.
https://doi.org/10.1007/s11064- 005- 7867- 3.
38. Tepper DE, Tepper SJ, Sheftell FD, Bigal ME.Headache attributed to hypothyroidism. Curr
Pain Headache Rep. 2007;11(4):304–9.
39. Gifn NJ, Kowacs F, Libri V, Williams P, Goadsby PJ, Kaube H.Effect of the adenosine A1
receptor agonist GR79236 on trigeminal nociception with blink reex recordings in healthy
human subjects. Cephalalgia. 2003;23(4):287–92.
00511.x.
40. Khawaja NM, Taher BM, Barham ME, Naser AA, Hadidy AM, Ahmad AT, Hamamy HA,
Yaghi NA, Ajlouni KM. Pituitary enlargement in patients with primary hypothyroidism.
Endocr Pract. 2006;12(1):29–34. https://doi.org/10.4158/EP.12.1.29.
41. Arafah BM, Prunty D, Ybarra J, Hlavin ML, Selman WR.The dominant role of increased
intrasellar pressure in the pathogenesis of hypopituitarism, hyperprolactinemia, and headaches
in patients with pituitary adenomas. J Clin Endocrinol Metab. 2000;85(5):1789–93. https://doi.
org/10.1210/jcem.85.5.6611.
42. Levy MJ, Jäger HR, Powell M, Matharu MS, Meeran K, Goadsby PJ.Pituitary volume and
headache: size is not everything. Arch Neurol. 2004;61(5):721–5. https://doi.org/10.1001/
archneur.61.5.721.
43. Tasnim S, Wilson SG, Walsh JP, Nyholt DR.Cross-trait genetic analyses indicate pleiotropy
and complex causal relationships between headache and thyroid function traits. Genes (Basel).
2022;14(1):16. Published 2022 Dec 21. https://doi.org/10.3390/genes14010016.
44. Tasnim S, Wilson SG, Walsh JP, Nyholt DR. Shared genetics and causal relationships between migraine and thyroid function traits. Cephalalgia. 2023;43(2) https://doi.
org/10.1177/03331024221139253.
45. Tasnim S, Nyholt DR.Migraine and thyroid dysfunction: co-occurrence, shared genes and
biological mechanisms. Eur J Neurol. 2003;30(6):1815–27.
46. Evans RW, Timm JS.New daily persistent headache caused by a multinodular goiter and headaches associated with thyroid disease. Headache. 2017;57(2):285–9.
47. Topliss DJ, White EL, Stockigt JR.Signicance of thyrotropin excess in untreated primary
adrenal insufciency. J Clin Endocrinol Metab. 1980;50(1):52–6. https://doi.org/10.1210/
jcem- 50- 1- 52.
48. Wilson SA, Stem LA, Bruehlman RD.Hypothyroidism: diagnosis and treatment. Am Fam
Physician. 2021;103(10):605–13.
49. Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, Cooper DS, Kim
BW, Peeters RP, Rosenthal MS, Sawka AM, American Thyroid Association Task Force on
Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by
the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid.
2014;24(12):1670–751. https://doi.org/10.1089/thy.2014.0028. PMID: 25266247; PMCID:
PMC4267409.
https://doi.org/10.1016/s0304- 3959(02)00070- 2.
https://doi.org/10.1007/s11916- 007- 0208- 2.
https://doi.org/10.1046/j.1468- 2982.2003.
P. G. Ferreira et al.

Chapter 44
Cardiac Cephalalgia
Viníciusda SilvaLessadeOliveira , VictorAlfonsoGarciaOrtiz ,
andVaniseGrassi
44.1 Introduction
The term “cardiac headache” was initially introduced by Lipton etal. in 1997, following the report of two cases of exertional headache. Their study detailed two male
patients, aged 57 and 67, who experienced headache developing 5–15minutes after
the onset of vigorous exercise, with improvement occurring minutes or hours after
cessation of the activity [1]. A subsequent literature review identied similar case
reports, demonstrating that symptoms either decreased or resolved completely with
pharmacological and/or surgical interventions aimed at correcting myocardial ischemia [2].
Since it is a rare condition among headaches, the literature primarily consists of
case reports, making it challenging to establish robust diagnostic criteria [3]. This is
partly due to its atypical presentation, with an absence of specic neurological signs
and variability in pain characteristics, which may mimic primary headaches [4].
Additionally, cardiac headache can be an isolated manifestation of myocardial
V. da SilvaLessadeOliveira
Postgraduate Program in Medicine, Pediatrics, and Child Health, Pontifícia Universidade
Católica do Rio Grande do Sul, Porto Alegre, Brazil
V. A. G. Ortiz
Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil
V. Grassi (
Department of Neurology, Hospital São Lucas da Pontifícia Universidade Católica do Rio
Grande do Sul, Porto Alegre, Brazil
Switzerland AG 2026
D. Uludüz et al. (eds.), Rare Causes of Headache Disorders, Headache,
https://doi.org/10.1007/978-3-032-10242-3_44
*)
417© The Author(s), under exclusive license to Springer Nature

418
V. da SilvaLessadeOliveira et al.
ischemia, frequently underdiagnosed due to low awareness and its unconventional
presentation. Unlike typical angina, which is characterized by oppressive chest pain
radiating to the arm and jaw, cardiac headache can occur in isolation, triggered by
physical exertion [5]. Therefore, a detailed clinical approach—based on medical
history, cardiovascular risk factor assessment, and complementary exams such as
stress tests and coronary angiography—is essential for differential diagnosis and
appropriate treatment of these patients [2, 3, 6–10].
44.2 Pathophysiology
While the precise pathophysiology of cardiac cephalalgia remains incompletely
understood, several key hypotheses are gaining increasing acceptance. First,
referred pain is the most widely cited mechanism, supported by numerous articles and case reports. This theory posits that the association between headache
and chest pain arises from the somatic nervous system via its visceral afferent
and efferent bers. Cardiac stimuli are detected by cardiac nociceptors and
ascend through afferent pathways, including the spinothalamic and spinoreticular tracts, ultimately reaching the sensory cortex and manifesting as a headache
[2, 5, 11]. The parasympathetic autonomic nervous system also plays a role, with
vagal nerve (cranial nerve X) afferent bers terminating in the nucleus of the
solitary tract. These bers connect with spinothalamic tract neurons, further contributing to cortical activation and headache generation [3]. Notably, some
ascending neurons synapse at the C1–C2 levels, connecting with the trigeminal
nerve (cranial nerve V) nucleus, which explains the potential for shoulder and
jaw pain in these patients [5, 12].
Second, transient intracranial hypertension is proposed as another mechanism
[13]. Following acute myocardial ischemia, reduced cardiac output diminishes the
heart’s pumping capacity, impacting systemic venous return, including cerebral
venous drainage. This disruption alters cerebral blood ow, leading to increased
cerebral perfusion pressure and, consequently, intracranial pressure [13].
The third and last hypothesis suggests that inammatory mediators are implicated in cardiac cephalalgia. Acute myocardial injury triggers the release of proinammatory substances from the cardiac muscle, such as bradykinin, serotonin,
substance P, histamine, and adenosine. These mediators can induce cerebral edema,
cerebral artery vasodilation, and cerebral cortical hypoperfusion, ultimately manifesting as a headache [2, 5].

44 Cardiac Cephalalgia
419
44.3 Case Presentation
A 61-year-old male with a history of hypertension, managed with regular antihypertensive therapy, and obesity presented to the emergency department with acute precordial pain. The pain began approximately 30minutes prior while the patient was
at rest at home. He described the pain as oppressive, retrosternal, and radiating to
the left shoulder and upper limb, accompanied by dyspnea, nausea, and a single
episode of emesis. Concurrently, the patient experienced a severe, acute-onset headache localized to the vertex, characterized as oppressive and increasing in intensity
with the worsening chest pain. Upon arrival, vital signs revealed a blood pressure of
145/80 mmHg; other vital signs were unremarkable. Neurological examination
revealed no focal decits or abnormalities. An electrocardiogram (ECG) demonstrated ST-segment elevation greater than 1.5mm in leads II, III, and aVF.An ultrasensitive troponin level was elevated at 1500 ng/L. Laboratory investigations
showed inammatory markers within normal limits and no evidence of autoimmune
or infectious etiologies. A computed tomography (CT) scan of the head revealed
normal anatomical ndings, without evidence of hemorrhage, mass lesions, or other
abnormalities. The patient was transferred to the cardiac catheterization laboratory,
where primary percutaneous coronary intervention (PCI) revealed a 90% occlusion
of the right coronary artery. Following PCI, the patient reported signicant improvement in both chest pain and headache.
44.4 Case Discussion
The rarity of cardiac cephalalgia makes its diagnosis complex, given its varied clinical presentation [3]. The literature suggests a patient prole typically over 50years
old male exhibiting established cardiovascular risk factors including systemic arterial hypertension, dyslipidemia, obesity, and a smoking history [14–19]. However,
this is not absolute, as cases have been reported in younger individuals and in
patients without cardiovascular risk factors [13, 20, 21].
Cardiac headache is frequently described as diffuse or localized to the vertex and
can be either unilateral or bilateral. Its presentation is characterized by a rapidonset, intense, and oppressive headache, sometimes described as a sensation that the
head is about to explode [4, 10, 15, 18, 19, 22, 23]. Patients generally deny photophobia and phonophobia [11, 19, 24, 25]. Nausea and signs and symptoms of myocardial ischemia, such as retrosternal, epigastric, or left upper limb pain, may
accompany the headache [4, 18, 24, 26]. Cardiac headache is usually triggered by
physical exertion, including activities such as sexual activity or walking, and generally improves soon after stopping the activity [1, 8, 27].

420
V. da SilvaLessadeOliveira et al.
Although age is a relevant factor in the anamnesis, other characteristics must be
carefully assessed for proper patient identication. Gathering information about
headache presentation, similarity to previous typical headache episodes, and
response to commonly used headache medications is crucial [28]. Additionally,
investigating the presence of comorbidities, as previously mentioned, should be part
of the patient’s evaluation.
The assessment of these patients involves stress testing, which usually reveals
recurrent headaches associated with ST-segment depression, and coronary angiography [2, 3, 7–10]. A review, involving 30 patients, reinforced the importance of
performing brain magnetic resonance imaging (MRI) to exclude other underlying
pathological conditions [6]. Regarding treatment, the triptans, as selective 5-HT
1B-1D
receptor agonists, promote vasoconstriction of extracerebral and intracranial arteries in migraine treatment, but they also exert a mild vasoconstrictive effect on coronary arteries [6]. This justies why triptans are contraindicated for patients with
cardiovascular disease, whereas improvement is seen with nitrate administration or
surgical intervention (bypass, myocardial revascularization, percutaneous transluminal coronary angioplasty, stenting) [1, 6, 8, 22, 23]. Furthermore, the literature
has emphasized that the immediate relief achieved with nitrate administration is a
consistent characteristic linking headaches to myocardial ischemia [7]. The adverse
reaction to triptan administration may aid in the identication of cardiac headache [13].
44.5 Headache Characteristics ofCardiac Cephalalgia
A summary of headache characteristics and associated symptoms from the literature
is presented in Table44.1.

44 Cardiac Cephalalgia
Multivessel
bypass surgery
C (1;
ICHD-3
Associated
signs and
2a,b)
criteria Intervention
Pain radiating
to the shoulders
symptoms
Antianginal
C (1;
Two-stage
therapy
C (1;
2a,b)
symptoms
denied
revascularization
with drug-eluting
stents;
individualized
therapy with dual
2a,b;
3c,d)
symptoms
denied
antiplatelet
therapy combined
with anticoagulant
therapy
Coronary
angioplasty
2a,b;
3a,c,d)
Stent
C (1;
2a,b;
3a,b)
diaphoresis,
nausea
421
(continued)
Triggering
or
aggravating
Headache
Onset
Sex
factors Relief factors
location Character Intensity
– Occipital – – Exertion Rest;
mode
Female
(Age)
Rest Associated
sublingual
nitroglycerine
– – Exertion
– Bilateral
Male
(56–60)
Rest Associated
cycling)
Oppressive Moderate Mild
– Vertex;
Female
exertion
bilateral
(74)
(running or
temporal
(40)
frontal
Exertion Rest – C (1;
on the
visual
– Severe (10
hemicrania
and facial
Acute Left
Female
(68)
analogue
scale)
headache
– – – Severe – – Dizziness,
Female
(81)
Wang and
Lin (2008)
Martínez
etal. (2002)
Ortiz etal.
Blacky etal.
Rambihar
(year)
(2001) [29]
Table 44.1 Case reports found in the literature review
Author
(1987) [30]
(2019) [11]
[3]
[25]

422
ICHD-3
criteria Intervention
Associated
signs and
symptoms
Myocardial
revascularization
C (1;
2a,b;
3a,c,d)
denied
associated
symptoms. In
another
episode, he
reported the
Stent
2a,b;
presence of
chest tightness
Coronary artery
bypass
C (1;
2a,b;
3c,d)
3a,d, 4)
Retrosternal
pain and
occasional
V. da SilvaLessadeOliveira et al.
Percutaneous
transluminal
coronary
angiography,
stenting of LAD,
and bifurcation of
the rst diagonal
and the RCA
C (1;
2a,b;
3a,c, d)
radiating to
upper limbs,
chest
discomfort,
palpitations,
cold sweating,
and facial
numbness of
both arms
pallor
Triggering
or
aggravating
Headache
Onset
Sex
factors Relief factors
– Severe Exertion – Initially, he
location Character Intensity
Acute Occipital
mode
Male
(Age)
(left)
(58)
– – – – C (1;
Non-
throbbing
parietal
– Bilateral
Male
(55)
Sublingual
nitroglycerin
exertion
– Bregmatic – Severe Stress and
Male
(62)
Nitrates Occasionally
cold
stimuli, and
sexual
Pulsatile Severe Exertion,
temporal
– Bilateral
Male
(40)
activities
Table 44.1 (continued)
Author
(year)
Sathirapanya
Wang etal.
Lefkowitz
and Biller
Cutrer and
Huerter
(2004) [19]
(2006) [14]
(1982) [18]
(2017) [31]

44 Cardiac Cephalalgia
423
(continued)
Nitrate and
calcium channel
blockers
C (1;
2a,b)
roof of the
mouth and
down both
arms, tightness
– Radiated to the
temperature
variation
Percutaneous
coronary
2a,b)
in the chest
angioplasty and
thrombus
nitroglycerin
aspiration
C (1) Sublingual
constrictive,
retrosternal
chest pain with
malaise, pallor,
reduced level of
consciousness,
and a mild
sensorimotor
decit of the
left upper and
lower limb
– Frontal – – Exertion,
Female
(78)
Fleetcroft
and
Maddocks
– – – – – – – C (1;
Female
(83)
Sun etal.
(1985) [12]
(2021) [13]
– – – – – – Severe,
Male
(40)
Latte etal.
(1996) [26]

424
ICHD-3
criteria Intervention
nitroglycerin
C (2a) Sublingual
bypass
2a,b;
3d)
Stent
B; C (1;
3a)
Coronary artery
V. da SilvaLessadeOliveira et al.
Nitroglycerin,
aspirin,
enoxaparin,
captopril, and
metoprolol
B; C (1;
3a, c, 4)
Stent, aspirin,
clopidogrel,
atorvastatin,
bisoprolol,
ramipril and
C (1;
2a,b; 3c)
lansoprazole
Associated
signs and
Triggering
or
aggravating
Headache
Onset
symptoms
discomfort and
factors Relief factors
Rest – Chest
Moderate-
to- severe
–
occipital
location Character Intensity
– Vertex;
mode
slight
diaphoresis
– – – – Exertion – – C (1;
Chest
discomfort
sublingual
– Severe Exertion Rest or
bilateral
Acute Vertex,
as shortness of
nitroglycerin
– – Symptoms such
Severe (10
out of
shooting
occipital,
eyeball
Acute – Sharp or
breath and
discomfort in
the chest, arm,
10in
severity)
jaw, neck, or
abdomen are
denied
in the chest
Acute – Oppressive Severe – – Warm sensation
Table 44.1 (continued)
Sex
(Age)
Author
(year)
Male
(59)
Gutiérrez-
Morlote and
Pascual
Male
Lance and
(2002) [16]
Female,
(62)
Wei and
Lambros
(1998) [17]
Male
(36–85)
Wang (2008)
[28]
Male
(70)
Famularo
etal. (2002)
[15]
Male
(64)
Lazari etal.
(2019) [32]
Соседние файлы в папке Библиотека им академика М.И. Перельмана
